Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma

被引：13
|
作者：
Boccon-Gibod, Clementine [1 ,2 ]
Talbot, Alexis [1 ,2 ]
Le Bras, Fabien [3 ,4 ]
Frenzel, Laurent [5 ,6 ,7 ]
Royer, Bruno [1 ,2 ]
Harel, Stephanie [1 ,2 ]
Lombion, Naelle [1 ,2 ]
Belhadj, Karim [3 ,4 ]
Cuccuini, Wendy [8 ]
Arnulf, Bertrand [1 ,2 ]
机构：
[1] Hop St Louis, AP HP, Immunohematol Dept, Paris, France
[2] Univ Paris Diderot Paris VII, Sorbonne Paris Cite, Paris, France
[3] Henri Mondor Hosp, Lymphoid Malignancies Unit, Creteil, France
[4] Mondor Amyloidosis Network, Creteil, France
[5] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Dept Hematol, Paris, France
[6] Univ Paris 05, Hop Necker Enfants Malad, AP HP, INSERM,U1163,Inst Imagine, Paris, France
[7] Univ Paris 05, Hop Necker Enfants Malad, AP HP, CNRS,ERL8654, Paris, France
[8] Hop St Louis, Dept Cytogenet, Paris, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 03期
关键词：
relapsed refractory multiple myeloma; venetoclax; carfilzomib; t(11; 14); EFFICACY;
D O I：
10.1111/bjh.16483
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E73 / E76
页数：4
相关论文
共 50 条
  • [1] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Costa, Luciano J.
    Davies, Faith E.
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Hong, Wan-Jen
    Dail, Monique
    Salem, Ahmed Hamed
    Yang, Xiaoqing
    Masud, Abdullah A.
    Munasinghe, Wijith
    Ross, Jeremy A.
    Bueno, Orlando F.
    Kumar, Shaji K.
    Stadtmauer, Edward A.
    [J]. BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
  • [2] Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Stadtmauer, Edward A.
    Morgan, Gareth
    Monohan, Gregory
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Mobasher, Mehrdad
    Freise, Kevin J.
    Ross, Jeremy A.
    Pesko, John
    Munasinghe, Wijith
    Gudipati, Saketh
    Mudd, Sarah
    Bueno, Orlando
    Kumar, Shaji K.
    [J]. BLOOD, 2018, 132
  • [3] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa, Luciano J.
    Stadtmauer, Edward Allen
    Morgan, Gareth John
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej J.
    Mobasher, Mehrdad
    Freise, Kevin
    Ross, Jeremy A.
    Pesko, John Carl
    Munasinghe, Wijith
    Cordero, Jaclyn
    Morris, Lura
    Maciag, Paulo Cesar
    Bueno, Orlando
    Kumar, Shaji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
    Shah, Jatin J.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Cohen, Adam D.
    Bensinger, William I.
    Gasparetto, Cristina
    Kaufman, Jonathan L.
    Lentzsch, Suzanne
    Vogl, Dan T.
    Gomes, Christina L.
    Pascucci, Natalia
    Smith, David D.
    Orlowski, Robert Z.
    Durie, Brian G. M.
    [J]. BLOOD, 2015, 126 (20) : 2284 - 2290
  • [5] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    [J]. BLOOD, 2019, 134 (05) : 421 - 431
  • [6] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
    Juan Du
    Baijun Fang
    Jian Li
    Jie Jin
    Shunqing Wang
    Dehui Zou
    Zhen Cai
    Hongxiang Wang
    Jianda Hu
    Wei Li
    Chengcheng Fu
    Zonghong Shao
    Zhongjun Xia
    Peng Liu
    Ting Niu
    En-Tzu Tang
    Amy S. Kimball
    Jian Hou
    Wenming Chen
    [J]. International Journal of Hematology, 2021, 113 : 422 - 429
  • [7] CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Ri, M.
    Suzuki, K.
    Chou, T.
    Sugiura, I.
    Takezako, N.
    Sunami, K.
    Ishida, T.
    Izumi, T.
    Ozaki, S.
    Iida, S.
    [J]. HAEMATOLOGICA, 2016, 101 : 787 - 788
  • [8] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
    Du, Juan
    Fang, Baijun
    Li, Jian
    Jin, Jie
    Wang, Shunqing
    Zou, Dehui
    Cai, Zhen
    Wang, Hongxiang
    Hu, Jianda
    Li, Wei
    Fu, Chengcheng
    Shao, Zonghong
    Xia, Zhongjun
    Liu, Peng
    Niu, Ting
    Tang, En-Tzu
    Kimball, Amy S.
    Hou, Jian
    Chen, Wenming
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 422 - 429
  • [9] Carfilzomib In Relapsed, or Relapsed and Refractory, Multiple Myeloma
    McCormack, Paul L.
    [J]. DRUGS, 2012, 72 (15) : 2023 - 2032
  • [10] Carfilzomib for relapsed and refractory multiple myeloma
    Groen, K.
    van de Donk, N. W. C. J.
    Stege, C. A. M.
    Zweegman, S.
    Nijhof, I. S.
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2663 - 2675
12345